🧠🎤 We are pleased to announce that Lys Therapeutics will present new data at #ADPD2026 in #Copenhagen this week.

Our CEO & co-founder, Dr. Manuel Blanc, will deliver an #oral presentation highlighting new preclinical results from our monoclonal antibody program targeting the tPA–NMDAr pathway in Parkinson’s disease.

Presentation details:

“A novel monoclonal antibody counteracting tPA/NMDAR-mediated neurotoxicity and BBB disruption in Parkinson’s disease”

Session time: March 21, 15:10–15:25

Abstract ID: 620

The study demonstrates that our antibody prevents #neuroinflammation and dopaminergic #neurodegeneration across multiple in vitro and in vivo models of Parkinson’s disease. Importantly, therapeutic efficacy was maintained even when treatment was initiated at later stages of disease progression, a key aspect for #clinical translation. Treatment also reduced plasma #biomarkers of neuronal damage and inflammatory cytokines, consistent with disease-modifying activity.

These findings further support the therapeutic potential of targeting the tPA–NMDAr interaction to protect the neurovascular unit and slow neurodegeneration.

#LYS241 is currently advancing through IND/CTA-enabling studies in preparation for future clinical trials.

We look forward to engaging with the scientific and clinical community at AD/PD 2026.

#ADPD2026 #ParkinsonsDisease #Neurodegeneration #Biotech #Neuroscience #DrugDevelopment